Key Takeaway: Foghorn Therapeutics has provided an update on its financials and corporate progress for the second quarter of 2026. The Phase 1 dose-escalation trial for FHD-909, targeting non-small cell lung cancer, is proceeding as scheduled. Additionally, the company is advancing selective EP300 degraders aimed at treating multiple myeloma and other hematological malignancies, with an IND submission planned for 2027.
Market Sentiment Analysis
POSITIVE FACTORS
FHD-909 trial is advancing as planned.
Potential treatments for multiple myeloma are in development.
IND submission for selective EP300 degraders is targeted for 2027.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+56%
120-day peak, hindsight
Typical move
2.6%
average across 3 past catalysts
Cash runway
~57 mo
Minimal dilution risk
Lead asset
FHD-286
Phase 2 · Small Cell Lung Cancer
Full Press Release Details
- FHD-909 (LY4050784) Phase 1 dose-escalation trial advancing as planned with non-small cell lung cancer (NSCLC) as the primary target population - Selective EP300 degraders with potential to treat multiple myeloma and other hematological malignancies advancing; IND targeted in 2027 - Accelerating
Frequently Asked Questions
What is the primary target of the FHD-909 trial?
The primary target population for the FHD-909 trial is non-small cell lung cancer.
When is the IND submission for EP300 degraders planned?
The IND submission for selective EP300 degraders is targeted for 2027.
What type of malignancies are EP300 degraders aimed at?
EP300 degraders are being developed to treat multiple myeloma and other hematological malignancies.
How is the FHD-909 trial progressing?
The Phase 1 dose-escalation trial for FHD-909 is advancing as planned.